Centro Médico Teknon
Dr. Luis Madero is a pediatric oncologist with 37 years of experience in treating blood disorders, bone marrow transplant, ablation therapy, and other diseases. He is a member of several associations and has extensive experience in his field.
Dr. Jesus Soberino is an oncologist at Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO). He specializes in breast cancer and melanoma. Dr. Soberino has led many phase 1–3 clinical trials. His work has helped approve important drugs, including CDK4/6 inhibitors for metastatic breast cancer and immunotherapies for melanoma.
His areas of expertise include endocrine therapy, managing hormone resistance, and developing new immunotherapies. Dr. Soberino is known for his patient-centered care. He actively collaborates in research to improve cancer treatment. He is accredited by VHIO and is a key member of the Breast Cancer and Melanoma Units.
Dr. Niko Mihic is a Family Medicine specialist with 15 years of experience in Emergency Medicine at McGill and University of Montreal Teaching Hospitals. He completed his training at Laval University in Quebec. Dr. Mihic has published many articles and has worked as a lecturer at the University of Montreal.
For the past 12 years, Dr. Mihic has practiced in Madrid, Spain. He runs private medical offices and teaches at St. Pablo CEU Medical School. He is the Chief of the Executive Health Program at Hospital de Madrid. Dr. Mihic also serves as a medical advisor for the European Space Agency and as National Consulting Physician for Air France and KLM.
Dr. Joan Albanell Mestres is a leading oncologist who specializes in breast cancer. He earned his MBBS from the University Autónoma de Barcelona in 1989. He leads the breast cancer program at HM Delfos and oversees Oncology services at Clin del Mar in Spain.
Dr. Albanell has published 120 scientific articles, with over 9,000 citations. He directs cancer research at Del Mar. He is also an active member of GEICAM, CIBERONC, AIECA, and SEOM. He regularly contributes to important oncology research.